CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs

CAR-T Digest - August 2020

14 April 2026: CrossBridge Bio enters an agreement to be acquired by Eli Lilly to advance next-generation dual-payload ADCs

CrossBridge Bio, Inc. has entered into a definitive agreement to be acquired by Eli Lilly and Company, marking a strategic deal to advance next-generation antibody-drug conjugate technologies in oncology
Under the terms of the agreement, CrossBridge Bio shareholders may receive up to $300 million in cash, including an upfront payment and additional milestone-based compensation
The acquisition provides Eli Lilly access to CrossBridge Bio’s innovative dual-payload ADC platform, designed to deliver synergistic therapeutic effects and overcome resistance mechanisms in cancer treatment
CrossBridge Bio’s pipeline is led by CBB-120, a TROP2-targeting dual-payload ADC combining a topoisomerase I inhibitor and an ATR inhibitor, with an Investigational New Drug filing anticipated in 2026
The dual-payload approach is designed to enhance the therapeutic index and generate more durable responses compared to existing TROP2-targeting ADCs